JP2022553329A5 - - Google Patents

Info

Publication number
JP2022553329A5
JP2022553329A5 JP2022523595A JP2022523595A JP2022553329A5 JP 2022553329 A5 JP2022553329 A5 JP 2022553329A5 JP 2022523595 A JP2022523595 A JP 2022523595A JP 2022523595 A JP2022523595 A JP 2022523595A JP 2022553329 A5 JP2022553329 A5 JP 2022553329A5
Authority
JP
Japan
Prior art keywords
human subject
tau
antibody
alzheimer
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022523595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553329A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/056676 external-priority patent/WO2021081101A1/en
Publication of JP2022553329A publication Critical patent/JP2022553329A/ja
Publication of JP2022553329A5 publication Critical patent/JP2022553329A5/ja
Priority to JP2025181171A priority Critical patent/JP2026012271A/ja
Pending legal-status Critical Current

Links

JP2022523595A 2019-10-22 2020-10-21 アルツハイマー病を治療するための抗ベータ-アミロイド抗体 Pending JP2022553329A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025181171A JP2026012271A (ja) 2019-10-22 2025-10-27 アルツハイマー病を治療するための抗ベータ-アミロイド抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962924633P 2019-10-22 2019-10-22
US62/924,633 2019-10-22
PCT/US2020/056676 WO2021081101A1 (en) 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for treating alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025181171A Division JP2026012271A (ja) 2019-10-22 2025-10-27 アルツハイマー病を治療するための抗ベータ-アミロイド抗体

Publications (2)

Publication Number Publication Date
JP2022553329A JP2022553329A (ja) 2022-12-22
JP2022553329A5 true JP2022553329A5 (cg-RX-API-DMAC10.html) 2023-10-30

Family

ID=73344157

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022523595A Pending JP2022553329A (ja) 2019-10-22 2020-10-21 アルツハイマー病を治療するための抗ベータ-アミロイド抗体
JP2025181171A Pending JP2026012271A (ja) 2019-10-22 2025-10-27 アルツハイマー病を治療するための抗ベータ-アミロイド抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025181171A Pending JP2026012271A (ja) 2019-10-22 2025-10-27 アルツハイマー病を治療するための抗ベータ-アミロイド抗体

Country Status (13)

Country Link
US (1) US20220372123A1 (cg-RX-API-DMAC10.html)
EP (1) EP4048695A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022553329A (cg-RX-API-DMAC10.html)
KR (1) KR20220084095A (cg-RX-API-DMAC10.html)
CN (1) CN114599393A (cg-RX-API-DMAC10.html)
AU (1) AU2020371612A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022007595A2 (cg-RX-API-DMAC10.html)
CA (1) CA3158513A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022004902A2 (cg-RX-API-DMAC10.html)
IL (1) IL292363A (cg-RX-API-DMAC10.html)
JO (1) JOP20220092A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022004678A (cg-RX-API-DMAC10.html)
WO (1) WO2021081101A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
EP3746476A1 (en) 2018-01-31 2020-12-09 Alector LLC Anti-ms4a4a antibodies and methods of use thereof
EP3746484A4 (en) 2018-01-31 2021-11-17 Alector LLC ANTI-MS4A6A ANTIBODY AND METHOD OF USING THEREOF
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2023081194A2 (en) * 2021-11-03 2023-05-11 Biogen Ma Inc. Methods for treating alzheimer's disease
KR20240142535A (ko) * 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법
WO2024086796A1 (en) * 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
EP4608432A4 (en) * 2022-10-25 2026-08-12 Inst For Basic Science Ibs EXTRACTION METHODS TO ENABLE CEREBRAL-SPINAL FLUID DRAINAGE
EP4455161A1 (en) 2023-04-24 2024-10-30 ONO Pharmaceutical Co., Ltd. Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies
WO2025059487A2 (en) 2023-09-15 2025-03-20 Othair Prothena Limited Cell penetrating agents and uses thereof
WO2025117721A1 (en) * 2023-11-27 2025-06-05 Massachusetts Institute Of Technology Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033325T2 (en) 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
US9040045B2 (en) * 2007-05-14 2015-05-26 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9221900B2 (en) * 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
EP2928494A4 (en) * 2012-12-07 2016-11-02 Biogen Internat Neuroscience Gmbh METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
MX2018015022A (es) * 2016-06-07 2019-08-14 Biogen Int Neuroscience Gmbh Métodos para el tratamiento de la enfermedad de alzheimer.

Similar Documents

Publication Publication Date Title
JP2023011002A (ja) アルツハイマー病の治療法
JP2026012271A (ja) アルツハイマー病を治療するための抗ベータ-アミロイド抗体
FRIBERG et al. Focal ischaemia caused by instability of cerebrovascular tone during attacks of hemiplegic migraine: a regional cerebral blood flow study
US8722042B2 (en) Use of ventricular enlargement rate in intravenous immunoglobulin treatment of alzheimer's disease
JP2025131566A5 (cg-RX-API-DMAC10.html)
JP2023520516A5 (cg-RX-API-DMAC10.html)
JP7319421B2 (ja) アルツハイマー病を治療するための抗aベータプロトフィブリル抗体及びベータ-セクレターゼbace1阻害剤を含む組成物
JP7792428B2 (ja) 抗アミロイドベータ抗体及びその使用
EP3823636A1 (en) Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
JP2024540294A5 (cg-RX-API-DMAC10.html)
Thurm et al. Effects of aging and mild cognitive impairment on electrophysiological correlates of performance monitoring
JP2025530190A (ja) アルツハイマー病治療のための免疫療法薬とscyllo-イノシトールとの組み合わせ
Pavlakis et al. Magnetic resonance spectroscopy in childhood AIDS encephalopathy
JP2024540294A (ja) アルツハイマー病を治療するための方法
Faerber et al. Cerebral MR of Menkes kinky-hair disease.
TW202313111A (zh) 治療阿茲海默症之方法
JP2023549075A5 (cg-RX-API-DMAC10.html)
Kes et al. Therapeutic Plasma Exchange in the Neurologic Intensive Care Setting: Recommendation for Clinical Practice
Rinaldi et al. Radio electric asymmetric conveyer (reac) neurobiological stimulation treatments in dysfunctional motor behavior in flail arm syndrome: A case report
Akter et al. Rasmussen’s Encephalitis in Children: A Case Report
HK40107811A (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
Beckmann et al. Dysphagia limit in multiple sclerosis
Hattori et al. A left parietooccipital lesion of 73-year-old male with right hemianopsia and sensory aphasia
Vainšteine et al. First Experience and the Effectiveness of Immunomodulating Treatment in Inflammatory Demyelinating CNS Diseases: Analysis of Nine Patients/Imūnmodulējošās Terapijas Efektivitāte Centrālās Nervu Sistēmas Iekaisīgu Saslimšanu Gadījumos: Deviņu Pacientu Analīze
JP2021183633A (ja) 再発型の多発性硬化症を治療するための方法